Company Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
The company’s partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
| Country | United States |
| Founded | 1979 |
| IPO Date | Feb 12, 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Jacqueline Shea |
Contact Details
Address: 660 West Germantown Pike, Suite 110 Plymouth Meeting, Pennsylvania 19462 United States | |
| Phone | 267 440 4200 |
| Website | inovio.com |
Stock Details
| Ticker Symbol | INO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001055726 |
| CUSIP Number | 45773H201 |
| ISIN Number | US45773H4092 |
| Employer ID | 33-0969592 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jacqueline E. Shea Ph.D. | Chief Executive Officer, President and Director |
| Peter D. Kies | Chief Financial Officer |
| Dr. Michael Sumner B.S., M.B.A., M.D. | Chief Medical Officer and Head of Development |
| Dr. Laurent M. Humeau Ph.D. | Chief Scientific Officer and Chairman of the Scientific Advisory Board |
| Thomas Hong | Manager of Investor Relations |
| Robert L. Crotty J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Jennie Willson | Director of Communications |
| E. J. Brandreth MBA | Senior Vice President of Quality Assurance |
| Dr. Jeffrey Skolnik | Senior Vice President of Clinical Development |
| Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing and Clinical Supply Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 30, 2026 | SCHEDULE 13G/A | Filing |
| Jan 27, 2026 | 424B5 | Filing |
| Jan 27, 2026 | 8-K | Current Report |
| Dec 29, 2025 | 8-K | Current Report |
| Dec 8, 2025 | SCHEDULE 13G/A | Filing |
| Dec 5, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |